Daewoong finishes resubmitting documents for Nabota to FDA
Daewoong Pharmaceutical’s botulinum toxin ‘Nabota’ has taken the last step to enter the U.S. market.
Daewoong Pharmaceutical(CEO Seung-Ho Jeon) announced on the 2nd that they turned in revised documents to the U.S. FDA and resumed the application process for Nabota’s sales approval in the U.S. T...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.